Welcome to our dedicated page for ALUMIS SEC filings (Ticker: ALMS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Alumis Inc. filings document material events for a Nasdaq-listed biopharmaceutical issuer, including 8-K reports on clinical data, corporate presentations, operating and financial results and capital-structure activity. The disclosures identify common stock listed under ALMS on The Nasdaq Global Select Market and note the company’s emerging growth company status.
The filing record covers envudeucitinib presentations and press releases, financial-results exhibits, common-stock offering disclosures, and shareholder voting matters from the annual meeting and proxy process. These documents frame the company’s governance, material agreements, capital structure and clinical or regulatory disclosure around its TYK2 inhibitor pipeline.
Alumis Inc. Chief Scientific Officer David M. Goldstein reported selling 2,596 shares of common stock on August 3, 2026 at a weighted average price of $26.37 per share. The sale was required under company policy to sell-to-cover tax obligations from vesting restricted stock units granted on July 29, 2025 and is described as non-discretionary. After the sale, he directly held 30,970 shares, including 2,177 shares acquired on May 20, 2026 under the 2024 Employee Stock Purchase Plan, plus additional indirect holdings through a family trust and family members.
ALUMIS INC.’s Chief Medical Officer, Jorn Drappa, reported a mandatory sale of 2,447 shares of common stock on August 3, 2026 at a weighted average price of $26.37 per share, in multiple trades between $25.54 and $26.42. The sale was executed under company policy as a sell-to-cover transaction to satisfy tax obligations arising from the vesting and settlement of restricted stock units granted on July 29, 2025, and is described as not a discretionary sale. Following these sales, Drappa directly holds 56,892 shares of Alumis common stock.
ALUMIS INC. Chief Development Officer Bradley Mark Christopher sold 2,572 shares of common stock on August 3, 2026 at a weighted average price of $26.37 per share in a sell-to-cover transaction to satisfy tax obligations from restricted stock unit vesting, and the sale is described as non-discretionary. The shares were sold in multiple transactions at prices ranging from $25.60 to $26.42. After this sale, he directly holds 48,533 shares, including 2,377 shares acquired on May 20, 2026 under the 2024 Employee Stock Purchase Plan. He also serves as trustee for two 2025 GRATs that hold shares, each receiving 20,026 shares transferred from related 2023 GRATs on October 30, 2025.
BlackRock, Inc. reports beneficial ownership of common stock of Alumis Inc. as a passive institutional investor. BlackRock and certain of its subsidiaries collectively beneficially own 7,069,502 shares of Alumis common stock, representing 5.7% of the outstanding class.
BlackRock has sole voting power over 6,948,664 shares and sole dispositive power over 7,069,502 shares, with no shared voting or dispositive power. Various underlying clients and funds have the right to receive dividends and sale proceeds, but no single such person holds more than five percent of Alumis’s outstanding common shares.
ALUMIS INC. Chief Legal Officer Sanam Pangali exercised stock options for 5,000 shares of common stock at $5.06 per share and sold 5,000 shares in an open-market transaction at $28.00 per share on July 6, 2026.
Following these transactions, Pangali directly owns 11,111 shares of Alumis common stock. The exercised options were granted under the company’s 2024 Equity Incentive Plan, with vesting tied to the executive’s continued service.
ALUMIS INC. director Lynn A. Tetrault reported receiving new equity awards consisting of restricted stock units and stock options. The filing shows a grant of 3,553 shares of common stock through RSUs at no cash cost and a stock option covering 15,528 shares with a fixed exercise price of $28.14 per share.
Both the RSUs and the option are scheduled to vest on the first anniversary of the grant date, and in any event will be fully vested by the issuer’s 2027 annual stockholder meeting, subject to her continuous service under the company’s 2024 Equity Incentive Plan. The awards will also vest in full upon a qualifying change in control if continuous service is maintained through that date.
ALUMIS INC. director Yao Zhengbin reported equity compensation grants, acquiring both restricted stock units and stock options rather than making any open‑market trades. He received 3,553 shares of Common Stock as a restricted stock unit (RSU) award at no cash cost.
He also received a stock option covering 15,528 shares of Common Stock at an exercise price of $28.14 per share, expiring on June 29, 2036. After the grants, he directly holds 27,082 Common shares. Both the RSUs and options vest on the first anniversary of the grant date, and will in any case be fully vested by the issuer’s 2027 annual stockholder meeting, with accelerated vesting upon a qualifying Change in Control, all subject to his continuous service under the company’s 2024 Equity Incentive Plan.
ALUMIS INC. director Sapna Srivastava received equity-based compensation in the form of restricted stock units and stock options. She was granted 3,553 shares of common stock issuable upon settlement of RSUs and an option covering 15,528 shares of common stock at an exercise price of $28.14 per share.
Both the RSUs and the option shares vest on the first anniversary of the grant date, and in any case will be fully vested on the date of the issuer's 2027 annual stockholder meeting, subject to her continuous service under the company’s 2024 Equity Incentive Plan. They will also vest in full upon a Change in Control, again subject to continuous service.
ALUMIS INC. director Patrick Machado reported new equity awards and his updated holdings. He received a grant of 3,553 shares of common stock as a restricted stock unit (RSU) award at no cost, which will vest on the first anniversary of the grant date or, in any case, by the company’s 2027 annual stockholder meeting, subject to continuous service or earlier vesting upon a Change in Control under the 2024 Equity Incentive Plan. He was also granted stock options for 15,528 shares of common stock at an exercise price of $28.14 per share, with the same vesting conditions. Following these awards, he holds 3,553 common shares directly and 7,064 common shares indirectly through the Patrick Machado Revocable Trust, where he serves as trustee, plus the newly granted options.